London close: Miners push Footsie higher
23rd Mar 2011 17:19
Footsie ended the day close to its high point though that was largely due to the strength of mining stocks rather than a rapturous reception to the UK Budget. What did get a rapturous reception, at least for a while, was the news that the voting by the Monetary Policy Committee in March on interest
Read moreTechMARK movers: Skyepharma ahead of expectations
23rd Mar 2011 16:00
Shares in Skyepharma jumped today after the drug delivery company reported better than expected figures. Revenues rose 4% to £58.1m in 2010 while flat operating profit of £15.3m was better than expected. This was achieved even though net R&D spending increased from £10.3m to £14.9m. Net debt has f
Read moreLondon afternoon: Housebuilders get Budget boost
23rd Mar 2011 15:00
It would appear that the UK Budget was far from a blockbuster as the market has reacted phlegmatically to the Chancellor's big day. The headline grabbing move was the commitment to effectively abolish National Insurance and push up income tax to compensate, but this will not take effect for some t
Read moreLondon midday: Back to square one
23rd Mar 2011 12:24
Footsie ended the morning more or less where it started it, as investors sit tight ahead of the Budget speech at 12:30pm. Resource stocks are in demand, with ENRC sitting atop a buoyant mining sector and Cairn leading oils higher. Underlying profits more than doubled last year at Kazakhstan-based
Read moreSkyepharma turns in annual profit
23rd Mar 2011 11:28
Drug developer Skyepharma hit a year high Wednesday after swinging into the black in 2010. Investors welcomed a profit before tax of £6.5m compared with a £0.9m loss a year ago as revenue increased 4% to £58.1m following a large rise in manufacturing revenues. The business also expects 2011 to be
Read moreSkyepharma ends production of PULMICORT
7th Mar 2011 16:13
The share price recovery of Skyepharma was brought to an abrupt halt Monday as the company said it is to stop production of its PULMICORT pressurised metered dose inhaler due to complex manufacturing issues related to technical aspects of the device. The device will remain on sale until existing
Read moreSector movers: Industrial transportation performing well
7th Mar 2011 13:24
Industrial transportation is the best performing sector, led by FTSE 250 groups Forth Ports and BBA Aviation. Forth Ports is higher after agreeing to let its major shareholder Arcus Capital go through its books ahead of a possible £16.30 bid that would value the Scotland-based port group at just sh
Read moreTechMARK movers: AstraZeneca drops SkyePharma product
7th Mar 2011 12:04
Shares in drug discovery company SkyePharma have slumped following news that AstraZeneca has decided to stop production of one of its drugs using SkyePharma's drug delivery technology. There were manufacturing problems because of technical aspects of the PULMICORT (budesonide) 100 and 200 µg/dose
Read moreTechMARK movers: ORA director joins Antisoma board
2nd Mar 2011 13:46
Antisoma has edged lower after further board changes that have led to Michael Bretherton, the finance director of 17.5% shareholder ORA, becoming a director. Antisoma chairman Barry Price and non-executive director Birgit Stattin-Norinder have both resigned. Grahame Cook takes over as chairman.
Read moreTechMARK movers: Thin trading moves prices
4th Jan 2011 13:29
There have been sharp price movements based on a handful of trades today. Drug developer SkyePharma is well ahead on the day even though less than 19,000 shares have been traded. Mobile radios supplier Sepura has fallen after around 32,000 shares were traded. E-learning group Promethean World c
Read moreTechMARK movers: Asian deal for Sinclair
7th Dec 2010 12:45
Shares in Sinclair Pharma are rising on the back of the collaboration with Invidia that will help to commercialise Sinclair's dermatology brands in Asia Pacific. The deal covers 11 markets and it is expected to last 20 years. The drugs will be launched over a three year period. Drug developer Sk
Read moreTechMARK movers: BT stake sale boost
26th Nov 2010 13:31
BT is higher after announcing that it is selling 5.5% of Indian IT Group Tech Mahindra to Mahindra & Mahindra. BT will still retain 24.4% of the IT company. The telecoms firm also benefited from an upbeat broker note from Exane BNP Paribas, which lifts its share price target for BT by 20% to 265p.
Read moreJapanese trials for Skyepharma's Flutiform
22nd Nov 2010 15:53
Drug delivery technology developer Skyepharma has been boosted by the commencement in Japan of phase III trials for Flutiform. Progress is ahead of schedule. There are two trials to confirm the efficacy and safety of Flutiform. Skyepharma's Japanese partner Kyorin will have to pay milestone paymen
Read moreUK SMALLCAP ROUNDUP: Skyepharma Slides On New Flutiform Blow
24th Jun 2010 16:00
Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps SKYEPHARMA PLC (SKP.LN) shares fell to a new low Thursday after the drug developer said its hopes of launching asthma treatment Flutiform in the U.S. wer
Read moreUPDATE: SkyePharma Falls On Latest Flutiform Blow
24th Jun 2010 15:16
(Adds detail and analyst comment.) By Jason Douglas Of DOW JONES NEWSWIRES LONDON (Dow Jones)--Shares in SkyePharma PLC (SKP.LN) fell to a new low Thursday after the drug developer said its hopes of launching asthma treatment Flutiform in the U.S. were dealt what's likely to be a final blo
Read more